Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RevMikeB who wrote (23237)	7/15/1998 12:49:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Trials to use Panretin (in combination with Tamoxifen) to treat breast cancer in humans began over a year ago (in a couple of government sponsored trials). Targretin is slated to begin clinical trials (at the Phase II level) for breast cancer soon. It's not clear if it will be best to target advanced or early disease or to use it as mono or combination therapy. LGND has breast cancer as a high priority for Targretin, but as you know, they have many "high priority" items (including the Targretin oral NDA for CTCL).